Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Coherus Oncology, Inc.NASDAQ: CHRS
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$23.68M, compared with $10.86M a year earlier. Trailing-twelve-month change in working capital was -$69.52M. Over 3 fiscal years it compounded at -58.1% a year.
Context
- Change in working capital amounted to 13.9% of revenue in FY2025, down 7.1 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly change in working capital holds near -$23.68M or moves back toward the trailing-twelve-month quarterly average of -$17.38M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (5.84M) USD
- Year-over-year change
- -110.5%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.84M) | -110.5% |
| FY2024 | 2024-12-31 | 55.89M | +251.8% |
| FY2023 | 2023-12-31 | (36.83M) | +53.5% |
| FY2022 | 2022-12-31 | (79.26M) | -287.1% |
| FY2021 | 2021-12-31 | 42.36M | — |
Change in Working Capital vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 change in working capital of $69.52M is the largest of the 11 companies compared; the peer median is $4.41M.
- Its year-over-year change of -189.0% is the 10th highest of 11, against a peer median of -25.2%.
- Change in working capital amounts to 148.3% of revenue for CHRS, versus a peer median of 25.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $69.52M | -189.0% | -58.1% | 148.3% | |
| LTM Mar 2026 | $23.74M | +149.1% | +20.4% | 68.1% | |
| LTM Mar 2026 | $14.87M | -22.8% | +6.9% | 26.6% | |
| LTM Mar 2026 | $7.29M | -27.6% | -23.0% | 25.2% | |
| LTM Mar 2026 | $5.72M | -37.2% | -5.6% | 7.5% | |
| LTM Mar 2026 | $5.7M | -57.2% | -62.8% | 16.5% | |
| LTM Mar 2026 | $4.58M | -40.8% | -33.2% | 5.9% | |
| LTM Mar 2026 | $4.24M | -538.4% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $3.89M | +220.7% | — | 199.6% |
| LTM Sep 2026 | $3.66M | +151.2% | — | — | |
| LTM Mar 2026 | $1.57M | +169.6% | — | 2652.5% | |
| Peer median (excluding CHRS) | $4.41M | -25.2% | -14.3% | 25.9% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | 168.02M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| Deferred Income Tax | 9.44M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 51.36M | 50.74M | 43.11M | 27.8M | 16.97M |
| Change in Working Capital | 42.36M | (79.26M) | (36.83M) | 55.89M | (5.84M) |
| Accounts Receivables | 34.06M | 13.05M | (150.68M) | 149.35M | 93.56M |
| Inventory | (6.25M) | (47.35M) | (46.73M) | (31.95M) | (17.11M) |
| Accounts Payables | 874K | (4.55M) | 23.76M | (3.94M) | (19.56M) |
| Other Working Capital | 13.68M | (40.41M) | 136.83M | (57.57M) | (62.74M) |
| Other Non-Cash Items | 143.05M | 75.45M | 52.93M | (137.92M) | (321.59M) |
| Operating Cash Flow | (37.43M) | (241.12M) | (174.88M) | (20.44M) | (138.51M) |
| Capital Expenditures | (1.29M) | (2.04M) | (286K) | 0 | 0 |
| Acquisitions (Net) | 1.29M | 0 | 845K | 0 | 0 |
| Purchases of Investments | (182.49M) | (127.38M) | (19.51M) | 0 | (103.84M) |
| Sales of Investments | 181.36M | 0 | 157.64M | 14.89M | 21.46M |
| Other Investing Activities | (137.29M) | (37.43M) | 5.95M | 215.43M | 457.46M |
| Investing Cash Flow | (138.41M) | (166.85M) | 144.64M | 230.32M | 375.09M |
| Debt Repayment | (672K) | 49.93M | 0 | (223.41M) | (233.19M) |
| Common Stock Issued | 40.9M | 6.36M | 74.22M | 1.46M | 8.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54.3M | (1.96M) | (4.62M) | 34.98M | (48.77M) |
| Financing Cash Flow | 51.88M | 54.33M | 69.6M | (186.97M) | (273.71M) |
| Effect of Forex Changes | 0 | 0 | (12K) | 0 | 0 |
| Net Change in Cash | (123.96M) | (353.65M) | 39.34M | 22.91M | (37.13M) |
| Free Cash Flow | (38.72M) | (243.16M) | (175.17M) | (20.44M) | (138.51M) |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.